Comparative Pharmacology
Head-to-head clinical analysis: AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE versus NATURETIN 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE versus NATURETIN 5.
AZILSARTAN MEDOXOMIL AND CHLORTHALIDONE vs NATURETIN-5
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azilsartan medoxomil is an angiotensin II receptor antagonist that selectively blocks the binding of angiotensin II to AT1 receptors, reducing vasoconstriction and aldosterone secretion. Chlorthalidone is a thiazide-like diuretic that inhibits sodium reabsorption in the distal convoluted tubule, increasing sodium and water excretion.
Thiazide diuretic that inhibits sodium-chloride symporter in distal convoluted tubule, decreasing sodium and water reabsorption and reducing intravascular volume and blood pressure.
Azilsartan medoxomil 40 mg/chlorthalidone 12.5 mg or 25 mg orally once daily; maximum dose: azilsartan medoxomil 40 mg/chlorthalidone 25 mg per day.
5 mg orally once daily.
None Documented
None Documented
Azilsartan medoxomil: Terminal half-life approximately 11 hours. Chlorthalidone: Long terminal half-life of 40-60 hours (mean 47 hours), allowing once-daily dosing.
Terminal elimination half-life is approximately 18-24 hours; clinically, this supports once-daily dosing and requires renal function monitoring.
Azilsartan medoxomil: Approximately 55% of the dose is excreted in feces and 42% in urine, mostly as metabolites. Chlorthalidone: Primarily excreted unchanged in urine (50-70%) via tubular secretion; approximately 30% is excreted in feces via biliary elimination.
Primarily renal (70-80% as unchanged drug); the remainder (20-30%) is eliminated via biliary/fecal routes.
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic